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Bovine herpesvirus 1 (BHV-1), an alphaherpesvirus, is a major pathogen that causes respiratory and reproductive
infections. We observed tyrosine phosphorylation of a 95-kDa viral protein and dephosphorylation of 55- and 103-kDa cellular
proteins during the course of BHV-1 infection. We demonstrated BHV-1 glycoprotein E (gE) to be the tyrosine phosphorylated
viral protein by immunoprecipitation. Inhibition of phosphorylation of BHV-1 gE by tyrosine kinase inhibitors genistein and
tyrphostin AG1478 substantially lowered the viral titer in Madin-Darby bovine kidney cells. The decrease in viral titer was
directly proportional to the decrease in phosphorylation of the BHV-1 gE. Interestingly, these kinase inhibitors did not inhibit
the replication of the BHV-1 gE deletion mutant virion (BHV-1gED3.1). Our findings suggest that the wild-type BHV-1, with a
functional gE protein, uses a different pathway of signaling events than the BHV-1 gE deletion mutant in replication. Our
results indicate that the tyrosine phosphorylation of the cytoplasmic tail of BHV-1 gE is an important post-translational
modification of the functional protein. An application of this study may be the use of tyrosine kinase inhibitors in controlling
the BHV-1 infection. © 2000 Academic PressINTRODUCTION
Bovine herpesvirus type 1 (BHV-1), an alphaherpesvi-
rus (Roizman et al., 1992), causes respiratory and repro-
ductive disease in cattle (Gibbs and Rweyemamu, 1977).
BHV-1 infections involve a well-orchestrated interaction
of the virus with its host cell machinery. Phosphorylation
cycles form a major part of such virus–host interaction. A
phosphorylation cycle (Hardie, 1995) includes highly reg-
ulated phosphorylation events (catalyzed by protein ki-
nases) and dephosphorylation events (catalyzed by pro-
tein phosphatases). Several of the viral proteins are
phosphorylated. Phosphorylation of viral (Morrison et al.,
1998) and host cellular proteins (Qie et al., 1999) is an
important event during the course of the viral infection. In
particular, tyrosine phosphorylation is critical to the reg-
ulation of cell proliferation and differentiation (Schles-
singer and Ullrich, 1992). This regulation of cellular func-
tion makes tyrosine phosphorylation essential for
productive viral infection, as viruses have adapted to
replicate in cells at certain stages of cell cycle and/or
differentiation. For example, tyrosine phosphorylation of
cellular proteins occurs as a result of human immuno-
deficiency virus type-1 infection (Cohen et al., 1992).
Tyrosine phosphorylation of cellular proteins by Src-like
kinases during the course of coxsackie B3 virus infection
is necessary for effective replication (Huber et al., 1999).
1 To whom reprint requests should be addressed at Veterinary Science
ldg., Box 2175. Fax: (605) 688-6003. E-mail: christopher_chase@
dstate.edu.
159An active role of tyrosine phosphorylation has been sug-
gested in the entry of cytomegalovirus, another herpes-
virus (Keay and Baldwin, 1996).
Tyrosine kinase inhibitors are used to study the role of
tyrosine phosphorylation and/or related signaling path-
ways in cellular and viral processes. In this study, we
used both genistein (Mera et al., 1999) and tyrphostin
(Fuortes et al., 1999), which are potent tyrosine kinase
inhibitors. Genistein and tyrphostin inhibit Herpes-Sim-
plex-Virus (HSV-1) infection by lowering the phosphory-
lation of tyrosine phosphoproteins (Yura et al., 1993,
1997). Genistein and tyrphostin inhibit the tyrosine phos-
phorylation signaling pathway used by the pseudorabies
virus (Favoreel et al., 1999).
Herpesviral glycoproteins play a major role in the
infection process. Glycoproteins specified by herpesvi-
ruses are involved in the host–cell interactions essential
for a productive infection (Schwyzer and Ackerman,
1996). Alphaherpesvirus glycoprotein E (gE) homologues
share common protein motifs for tyrosine phosphoryla-
tion and sorting signals (Alconada et al., 1999). gE is
functionally conserved among the alphaherpesviruses
(Knapp and Enquist, 1997). BHV-1 gE plays a major role
in cell-to-cell spread and in virulence (Reberdosa et al.,
1996). gE enhances morbidity and mortality rates in in-
fected animals (Yang et al., 1999). Previous studies re-
vealed that BHV-1 gE and glycoprotein I (gI) form a
noncovalent complex soon after their synthesis and func-
tion as one unit (Whitbeck et al., 1996). BHV-1 gE–gI
complex is present in the cell plasma membrane, virus
envelope, and all the internal cell membranes (except
0042-6822/00 $35.00
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160 SHAW ET AL.the mitochondrial membranes) and plays an important
role in neurotropism of the alphaherpesviruses (Jacobs,
1994). The BHV-1 gE deletion mutant virus (BHV-1
gED3.1) and the tyrosine kinase inhibitors genistein and
tyrphostin AG1478 were used to study the biological
significance of BHV-1 gE tyrosine phosphorylation. We
provide evidence that tyrosine phosphorylation of BHV-1
gE is an important post-translational modification of the
functional protein.
RESULTS
BHV-1 infection and tyrosine phosphorylation
Tyrosine phosphorylation of proteins was identified
using a mouse monoclonal antibody to phosphotyrosine
(PY20) in a chemiluminescent assay. The specificity of
the PY20 antibody to the phosphotyrosine residues was
established using protein tyrosine phosphatase (PT-
FIG. 1. The effect of BHV-1 infection on tyrosine phosphorylation. This
was studied using uninfected cell lysates (lanes 1) and BHV-1-infected
cell lysates (lanes 2). The tyrosine phosphorylation was analyzed using
the PY20 antibody at 6, 12, and 20 h p.i. The tyrosine phosphorylated
proteins that changed pattern during BHV-1 infection are shown on the
right side, and the molecular weights are indicated on the left side. The
45-kDa host cellular tyrosine phosphorylated protein is the internal
control (IC).
T
Relationship between the Tyrosine P
Protein
0–6 h p.i. 6–12
C B C
103 kDa (CP) 2.5a 2.6a 5.2a
gE (95 kDa VP) 0a 2.0b 0a
55 kDa (CP) 5.0a 4.7a 5.0a
Note. The kinetics of the phosphoprotein expression are represented
(C), BHV-1 infected (B), infected in the presence of genistein (G), and in
the same row and treatment time with different superscripts are statistically si
the SAS program. The results are from an average of three experiments.Pase). The PY20 antibody failed to detect the PTPase-
treated tyrosine phosphorylated proteins in the cell ly-
sates (data not shown). The two major changes ob-
served in the levels of tyrosine phosphorylation during
BHV-1 infection in Madin-Darby bovine kidney (MDBK)
cells (Fig. 1) were the phosphorylation of a 95-kDa viral
protein (VP) and the dephosphorylation of two cellular
proteins (CPs) with molecular weights of 55 and 103 kDa.
The relationship of the level of phosphorylation among
these three proteins is shown in Table 1. The 95-kDa
tyrosine phosphorylated protein was present only in
BHV-1-infected cells. The protein was not a cellular
stress protein as it could not be induced by thermal
shock (42°C for 15 min), cold shock (14°C for 30 min),
chemical treatment (70% ethanol for 5 s), or infection with
an unrelated virus (vesicular stomatitis virus for 12 h)
(data not shown). This 95-kDa VP was detected as early
as 4 h postinfection (p.i.) and was dependent on the
multiplicity of infection (m.o.i.) (data not shown). The
phosphorylation of this protein increased with time and
reached a peak by 20 h p.i. (Fig. 1, lane 2, at 20 h p.i., and
Table 1).
The 55- and 103-kDa CPs are expressed in MDBK
cells as tyrosine phosphorylated proteins. There was a
50–60% (average of 55%, n 5 3 experiments) decrease in
phosphorylation of the 55-kDa CP observed from 12 h p.i.
through 20 h p.i. (Fig. 1, lane 2, at 6–12 and 12–20 h p.i.,
and Table 1). The level of phosphorylation of the 103-kDa
CP was reduced by almost 100% by 20 h p.i. (Fig. 1, lane
2, at 12–20 h p.i., and Table 1). The levels of 55 and 103
kDa were determined by comparison of chemilumines-
cent signal of each protein in virally infected cells with
the chemiluminescent signal of each protein in unin-
fected cells at each time point (Fig. 1). In addition to
these changes, we also observed a 46–50% (average of
48%, n 5 3 experiments) increase in the phosphorylation
f a 137-kDa cellular tyrosine phosphorylated protein at
0 h p.i. (Fig. 1, lane 2, at 12–20 h p.i.) compared with the
ninfected lane (Fig. 1, lane 1, at 12–20 h p.i.).
orylation of BHV-1 gE and the CPs
Time
12–20 h p.i.
B C B G T
.0a 5.1a 0b 4.0c 4.8a,c
.5b 0a 13.2b 8.5c 5.0d
.8b 4.9a 2.5b 4.5a 4.9a
relative phosphorylation (RTP) units. Cell lysates that were uninfected
in the presence of tyrphostin (T) were used in this study. Values withinABLE 1
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161TYROSINE PHOSPHORYLATION IN BHV-1 INFECTIONIdentifying the 95-kDa viral tyrosine phosphorylated
protein
The 95-kDa protein was immunoprecipitated from
BHV-1-infected cell lysate using a polyclonal goat anti-
BHV-1 sera, treated with PY20 antibody, and demon-
strated by chemiluminescence to be a BHV-1 tyrosine
phosphorylated protein (Fig. 2: lane 2). Three viral BHV-1
viral proteins, VP8, BICP0, and gE, were candidate phos-
phoproteins based on the molecular weight of 95 kDa. To
FIG. 2. Identifying the 95-kDa viral protein by immunoprecipitation.
Lanes 1–6 were visualized by the chemiluminescent detection system
after treatment with the PY20 antibody. Lanes 1 and 2, immunoprecipi-
tate of uninfected cell lysate and BHV-1-infected cell lysate with goat
polyclonal anti-BHV-1 sera, respectively; lane 3, immunoprecipitate of
BHV-1-infected cell lysate with murine monoclonal antibody to BHV-1
VP8; lane 4, immunoprecipitate of BHV-1-infected cell lysate with rabbit
polyclonal antisera to BHV-1 BICP0; lanes 5 and 6, immunoprecipitate
of uninfected cell lysate and BHV-1-infected cell lysates with rabbit
polyclonal antisera to BHV-1 gE, respectively; and lane 7, immunopre-
cipitate of BHV-1-infected cell lysate with rabbit polyclonal antisera to
BHV-1 gE visualized by Coomassie blue staining. The molecular weight
of the protein is indicated on the left side.FIG. 3. LDH release after treatment of MDBK cells with genistein averify the identify of this BHV-1 tyrosine phosphorylated
protein, similar immunoprecipitation and chemilumines-
cence studies (like those described) using anti-VP8 and
anti-BICP0, or anti-gE antibodies and PY20 antibody,
were conducted. Our results indicated that VP8 and
BICP0 proteins were not tyrosine phosphorylated (Fig. 2,
lanes 3 and 4). However, BHV-1 gE was a tyrosine phos-
phorylated protein (Fig. 2, lane 6). Uninfected cell lysates
were used as controls in these assays (Fig. 2, lanes 1
and 5). To further confirm the identity of the gE protein,
the membrane strip in lane 6 was stained with Coomas-
sie blue, and a band at 95 kDa was identified (Fig. 2, lane
7).
Optimization of dose for the tyrosine kinase inhibitors
Nontoxic levels for genistein and tyrphostin in MDBK
cells were determined by use of the trypan blue exclu-
sion test and lactate dehydrogenase release (LDH) as-
say. Genistein at 25 mM and tyrphostin at 12.5 mM were
etermined to be the optimal nontoxic doses based on
reater than 95% viability of cells by trypan blue (data not
hown) and less than 5% release of LDH (Fig. 3) after
4 h of treatment. DMSO, the solvent for both genistein
nd tyrphostin, had no cytotoxic effect at the dose used
Fig. 3).
he relationship between phosphorylation of gE and
he 55- and 103-kDa CP
The levels of tyrosine phosphorylation were measured
sing PY20 antibody and chemiluminescence on BHV-1-
nfected and tyrosine kinase inhibitor-treated BHV-1-in-
ected cell lysates at 20 h p.i. Genistein (Fig. 4, lane 3,
nd Table 1) and tyrphostin (Fig. 4, lane 4, and Table 1)
ecreased the phosphorylation of the gE protein while
ncreasing the phosphorylation of the 55- and 103-kDa
yrosine phosphorylated CPs compared with untreated
HV-1-infected controls (Fig. 4, lane 2, and Table 1).nd tyrphostin. The results are an average of triplicate trials.
a
a
162 SHAW ET AL.Genistein and tyrphostin reduced the phosphorylation of
gE by an average of 36% and 62%, respectively (Fig. 4,
lanes 3 and 4, and Table 1). The phosphorylation of the
55-kDa CP returned, in the presence of genistein and
tyrphostin, to levels identical to uninfected cell lysates
(Fig. 4, lane 1, and Table 1). No phosphorylated 103-kDa
protein could be detected in BHV-1-infected cells at 20 h
p.i. (Fig. 4, lane 2, and Table 1). However, the presence of
genistein or tyrphostin in BHV-1-infected cells main-
tained the phosphorylation of the 103-kDa CP at 80% or
95%, respectively (Fig. 4, lanes 3 and 4, and Table 1), of
the phosphorylation level of the uninfected cell lysate
(Fig. 4, lane 1, and Table 1). An additional observation
was that a 137-kDa cellular tyrosine phosphorylated pro-
tein, which increased in phosphorylation during the
course of infection, was unaffected by either of the in-
hibitors (Fig. 4, lanes 3 and 4).
The effect of tyrosine kinase inhibitors on BHV-1 and
BHV-1gED3.1 replication
The tyrosine kinase inhibitors decreased the titer of
wild-type BHV-1 in MDBK cells (Fig. 5). Tyrphostin had a
greater negative impact on the phosphorylation of gE
and thus lowered the viral titer to a greater extent than
did genistein. The inhibitors had no effect on the BHV-
1gED3.1 titers at 24 h p.i. in MDBK cells (Fig. 5).
DISCUSSION
Although the complete genome of BHV-1 has been
described, little work has been done in understanding
the signaling pathway used by the BHV-1 during infec-
tion. The initial approach was to determine whether
phosphorylation inhibitors regulated BHV-1 replication,
FIG. 4. The effect of tyrosine kinase inhibitors on tyrosine phosphor-
ylation during BHV-1 infection. MDBK cells were uninfected (lane 1) or
infected with BHV-1 (lane 2) or BHV-1 in the presence of genistein (lane
3) and tyrphostin (lane 4) respectively. The cell lysates were prepared
at 20 h p.i., resolved by SDS–PAGE, blotted onto a membrane, and
analyzed using PY20 antibody for tyrosine phosphorylation.so the effects of several compounds known to affect
phosphorylation were screened. The compounds tested
s
dincluded protein phosphatase inhibitors (sodium vana-
date, sodium fluoride, cypermethrin, dephostatin, oka-
daic acid, and tautomycin), serine/threonine kinase in-
hibitors (bisindolylmaleimide I, H-89, KN-93, KT 5823, and
KT 5926), and tyrosine kinase inhibitors (genistein and
tyrphostin AG1478) for their effects on the replication of
BHV-1. Of all of the compounds screened, we found
genistein and tyrphostin, tyrosine kinase inhibitors, to be
the most effective inhibitors of BHV-1 replication. Once
tyrosine phosphorylation was identified as an important
step of BHV-1 replication, we expected to identify
changes in the tyrosine phosphorylation of the viral and
the host cellular proteins after treatment with these in-
hibitors.
BHV-1 infection in MDBK cells produced two major
changes in tyrosine phosphorylation of the host cellular
proteins: the dephosphorylation of 55- and 103-kDa CPs
that occurred as an increase in phosphorylation of gE
was observed. The relationship between these phos-
phorylated proteins was studied by the use of tyrosine
kinase inhibitors genistein and tyrphostin. We chose two
tyrosine kinase inhibitors in our study for the following
reasons: (1) to confirm the specificity of the inhibition to
tyrosine kinase and (2) to determine whether the level of
inhibition was affected by mechanism of action because
the two tyrosine kinase inhibitors act by different mech-
FIG. 5. The effect of genistein and tyrphostin on BHV-1 and BHV-1
gED3.1 replication. The six columns termed BHV-1, gE-del BHV-1, BHV-
1/genistein, gE-del BHV-1/genistein, BHV-1/tyrphostin, and gE-del BHV-
1/tyrphostin denote titers of BHV-1, BHV-1 gED3.1, BHV-1, and gE-del
BHV-1 in the presence of 25 mM genistein and BHV-1 and gE-del BHV-1
in the presence of 12.5 mM tyrphostin at 24 h p.i. in MDBKs. The
verage titer is indicated above the bar. The results are from the
verage of triplicate trials. Mean values on the columns with different
uperscripts are statistically significant (P , 0.05) by least significance
ifference calculated using the SAS program.
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163TYROSINE PHOSPHORYLATION IN BHV-1 INFECTIONanisms. Genistein is an isoflavone that has multiple
activities besides the inhibition of tyrosine kinase. As a
tyrosine kinase inhibitor, genistein acts by binding to the
ATP binding site of the kinase (Akiyama et al., 1987),
whereas tyrphostins inhibit the tyrosine kinases by bind-
ing to the substrate binding site (Gazit et al., 1991). Our
esults indicated that tyrosine phosphorylation of the gE
as inhibited by both compounds. However, tyrphostin
as a better inhibitor of gE phosphorylation than
enistein (Table 1). This confirms the earlier reports that
yrphostins have higher inhibitory activity against ty-
osine kinases than genistein (Gazit et al., 1989). The
inhibitors used in this study decreased the phosphory-
lation of gE while increasing phosphorylation of the 55-
and 103-kDa CPs in a “dynamic balance relationship.”
This model supports the activation of a cellular PTPase
by BHV-1 infection that in turn dephosphorylates the 55-
and 103-kDa CPs. The significance of the increased
phosphorylation of the 137-kDa tyrosine phosphorylated
cellular protein during the infection remains unclear. We
did not analyze the relationship between phosphoryla-
tion and quantity of the 55-, 103-, and 137-kDa CPs during
BHV-1 infection. Hence, it would be premature to con-
clude that the levels of phosphorylation of 137-kDa CP
and dephosphorylation of 55- and 103-kDa CPs are in-
dependent of the relative quantity of the respective pro-
teins expressed during infection. The failure of these
inhibitors to affect cellular proteins may indicate a high
rate of turnover of the CPs and the cellular tyrosine
kinases. This could also indicate that viral protein phos-
phorylation was more sensitive to the kinase inhibitors.
BHV-1 gE was tyrosine phosphorylated during the
course of infection. BHV-1 gE is a viral envelope protein
classified as a g2 protein (Fields et al., 1996). The ty-
osine phosphorylated BHV-1 gE is homologous to gE
escribed in other alphaherpesviruses. The level of
mino acid identity between the ectodomain of BHV-1 gE
accession no. AJ004801.1) and varicella-zoster virus
VZV) gE (accession no. X04370.1) or pseudorabies virus
PRV) gE (accession no. M14336.1) or HSV-1 gE (acces-
ion no. X02138.1) was 29.66%, 31.48% and 31.96%, re-
pectively, as analyzed by Protein Information Resource
PIR) database/software (Barker et al., 1999). The level of
mino acid identity between the cytoplasmic tail of
HV-1 gE (accession no. AJ004801.1) and VZV gE (acces-
ion no. X04370.1) or PRV gE (accession no. M14336.1) or
SV-1 gE (accession no. X02138.1) was 20.00%, 34.59%,
nd 20.41%, respectively, as analyzed using the PIR soft-
are. A slightly higher amino acid identity between the
ytoplasmic tail of BHV-1 gE and PRV gE is probably the
eason for the ability of BHV-1gE to complement the
irulence defect of PRV lacking its own gE (Knapp and
nquist, 1997). Phosphorylation of envelope glycopro-
eins is a rare post-translational modification in the neu-
otropic alphaherpesviruses (Jacobs, 1994). Analysis of
he 575-amino-acid-long BHV-1 gE sequence (accession
c
bo. AJ004801.1) using PSORT program (Nakai, 1991) des-
gnated it as a type Ia transmembrane protein (Fig. 6).
he predicted structure of the protein is composed of a
ydrophilic extracellular domain spanning amino acid
esidues 1–423, a hydrophobic transmembrane region of
esidues 424–440, and a fairly long cytoplasmic tail of
esidues 441–575. The predicted cytoplasmic tail of the
HV-1 gE contains a conserved antigen recognition ac-
ivation motif (ARAM) that includes at least two YXXL
equences separated by six amino acids (amino acids
57–470). Tyrosine residues in these ARAMs are phos-
horylated and play a major role in signal transduction
ia the activation of protein tyrosine kinase pathway
Park and Scheiber, 1995). These ARAMs are present in
he cytoplasmic tail of several other transmembrane pro-
eins that function as tyrosine phosphorylated receptors,
uch as latent membrane protein 2A of Epstein–Barr
irus (Rowe et al., 1990), bovine leukemia virus gp30, and
everal components of the T and B cell receptors (Chan
t al., 1994). Alteration of the tyrosine residues (Letour-
eur and Klausner, 1992) or deletion of the C-terminal
eucine residue (Irving et al., 1994) within the ARAM
esulted in a markedly reduced receptor function or the
oss of receptor function. Interestingly, this ARAM region
s one of the most highly conserved domains within the
E homologues of BHV-1, simian varicella virus, feline
erpesvirus 1, equid herpesvirus 1, PRV, VZV, and HSV-1
Alconada et al., 1999). This domain is essential for the
ntracellular sorting of the protein (Zhu et al., 1996; Al-
onada et al., 1996; and Alconada et al., 1999) and in
ctivation of tyrosine phosphorylation signal transduc-
ion pathway (Favoreel et al., 1999). Recently, a single
XXL sequence in the cytoplasmic tail of the VZV gE
mino acid sequence has been implicated in tyrosine
hosphorylation. In this case, dimerization of VZV gE
eceptor molecule has been hypothesized to create a
erfect ARAM by the YXXL sequences in the two proteins
hat serve as a binding site for the Src homology 2
omain of tyrosine kinase (Olson et al., 1997). The BHV-1
E lacks any tyrosine kinase activity, and the kinases
FIG. 6. Membrane topology: type 1a. The cytoplasmic domain con-
tains a tyrosine phosphorylation motif (paired YXXL sequence) and a
putative casein kinase II phosphorylation site (SDDE). The arrow indi-
cates the possible cleavable signal peptide (amino acids 1–20).oded by the BHV-1 genome (accession: AJ004801) have
een identified to be only of the serine/threonine ki-
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164 SHAW ET AL.nases. Therefore, we hypothesize that BHV-1 gE is phos-
phorylated on its tyrosine residue by the host cellular
(non-receptor) tyrosine kinases to start a signaling cas-
cade. Thus BHV-1 gE is the latest addition to the small
family of VZV gE, HSV-1 gE, and PRV gE that are phos-
pho-gE proteins of alphaherpesviruses. The cytoplasmic
domain of BHV-1 gE amino acid sequence contains a
potential casein kinase II phosphorylation motif, SDDE
(amino acids 483–486). This motif is shared by other
substrate proteins, such as heat shock protein 90, simian
virus 40 large T antigen, and ornithine decarboxylase,
that undergo phosphorylation on serine residue by ca-
sein kinase II (Yao et al., 1993). Although we did not
demonstrate the phosphorylation of BHV-1 gE on its
serine residue, it carries a potential motif making it iden-
tical to all of the other phosphorylated gEs of alphaher-
pesviruses.
The gE protein is essential for the cell-to-cell spread of
the virus, especially in epithelial and nerve cells (Yoshi-
take et al., 1997). Our results indicate that inhibition of
phosphorylation of gE using tyrosine kinase inhibitors
lowers the viral titer in MDBK cells, an epithelial cell type.
Tyrphostin decreased phosphorylation of gE and low-
ered the viral titer more than genistein. The specificity of
these inhibitors for the inhibition of tyrosine phosphory-
lation of BHV-1 gE was confirmed using the BHV-1gED3.1.
However, results using the BHV-1gED3.1 clearly indicate
that gE is dispensable for in vitro replication, as docu-
mented earlier (Mettenleiter et al., 1985; Chowdhury et
al., 1999). An extension of our findings (Table 2) is that the
wild-type BHV-1, with an intact and functional gE protein,
uses a pathway of signaling events different from the
BHV-1 gE deletion mutant in replication. We are currently
involved in studying the signaling pathway used by the
BHV-1gED3.1 and the importance of the dephosphoryla-
tion of CPs.
Taken together, we conclude that tyrosine phosphor-
ylation of gE is one of the major signaling events in
wild-type BHV-1 infections. Inhibition of phosphorylation
TABLE 2
Comparison of Tyrosine Phosphorylation Events
during BHV-1 and BHV-1gED3.1 Infection
Properties BHV-1 BHV-1gED3.1
eplication in MDBKs 11 11
yrosine phosphorylation of gE 1 2
ffect of tyrosine kinase inhibitors
on viral replication 2 11
ffect of tyrosine kinase inhibitors
on gE phosphorylation 2 2
Note. 1 Indicates presence; 11, unrestricted replication of the
irus; 2, absence; and 2, negative regulation.of gE on its tyrosine residue impairs the function of the
protein. The inhibition of tyrosine phosphorylation of gE
s
mattenuates the viral titer, which suggests that this event
is important in BHV-1 replication and may be affecting
the intracellular transmission of a lethal signal by some
other route yet to be determined. Finally, an application
of this study is the possible use of tyrosine kinase inhib-
itors in control of the BHV-1 infection. Work using these
inhibitors to prevent gE phosphorylation may be of use in
preventing latency and infection by BHV-1.
MATERIALS AND METHODS
Cells
MDBK cells (American Type Culture Collection, Rock-
ville, MD) were used in this study. The cells were grown
in minimum essential media (GIBCO, Grand Island, NY)
containing 10% equine serum (Sigma Chemical Co., St.
Louis, MO).
Virus
Plaque-purified Cooper (Colorado-1) strain of BHV-1
(American Type Culture Collection) and the recombinant
glycoprotein gE gene-deleted BHV-1, BHV-1gED3.1
(kindly provided by S. I. Chowdhury, Kansas State Uni-
versity), were used in this study. The BHV-1gED3.1 con-
tains a chimeric b-gal gene regulated by a human cyto-
egalovirus immediate-early promoter in the place of
ost of the deleted gE coding sequence (encoding the
irst 372 of 575 amino acids) that has been previously
escribed (Chowdhury et al., 1999). BHV-1 and BHV-
gED3.1 were propagated and titrated in MDBK cells as
reviously described (Chase et al., 1989).
ntibodies and reagents
Murine monoclonal antibody to BHV-1 VP8 (a gift from
ikram Misra, University of Saskatchewan), rabbit poly-
lonal antisera to BHV-1 BICP0 (a gift from Martin Schw-
zer, University of Zurich), rabbit polyclonal antisera to
HV-1 gE (a gift from Lynn Enquist, Princeton University),
nd a goat polyclonal anti-BHV-1 sera (VMRD, Pullman,
A), were used to immunoprecipitate the BHV-1 protein.
mouse monoclonal antibody to phosphotyrosine (PY20;
albiochem, La Jolla, CA) conjugated to alkaline phos-
hatase was used to detect tyrosine phosphorylated
roteins.
Protein tyrosine phosphatase (Boehringer-Mannheim
iochemicals, Indianapolis, IN) was used to dephos-
horylate the phosphotyrosine residue to test the spec-
ficity of the PY20 antibody according to the manufactur-
r’s recommendations.
etection of tyrosine phosphorylated proteins
Actively dividing (70–75% confluent) MDBK cells
ere infected at 0.5 m.o.i. of BHV-1 in minimum es-ential media (MEM) containing 2% equine serum. The
ock-infected cells were treated with MEM containing
mA
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165TYROSINE PHOSPHORYLATION IN BHV-1 INFECTION2% equine serum and no virus. The cells were incu-
bated at 37°C for 6, 12, and 20 h p.i. At the end of each
time point, the cells were washed once in cold NET
buffer (Marshall et al., 1986) and lysed on ice using
lysis buffer (NET buffer containing 0.5% Nonidet P-40,
0.5% sodium deoxycholate, 100 U/ml aprotinin, 0.2 mM
sodium vanadate, 1 mM PMSF, and 2 mg/ml leupeptin).
Equal amounts of protein were loaded and resolved by
10% sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis (SDS–PAGE) and blotted onto a PVDF
membrane (Millipore, Bedford, MA) using a TE42
transfer tank (Hoefer Scientific Instruments, San Fran-
cisco, CA). The membrane was probed with PY20
antibody, treated with the Western-Light chemilumi-
nescent detection system (Tropix, Bedford, MA), and
exposed to X-ray film (Kodak X-OMAT; Sigma Chemical
Co.), and the image was digitalized and analyzed with
Molecular Analyst Software, version 2.1 (Bio-Rad, Her-
cules, CA). The level of the tyrosine phosphorylated
proteins was studied using the relative tyrosine phos-
phorylation (RTP) units. The RTP units are the ratio of
each of the tyrosine phosphorylated protein (55- and
103-kDa CPs and 95-kDa VP) compared with the inter-
nal control (45-kDa tyrosine phosphorylated host cel-
lular protein).
Immunoprecipitation
Actively dividing MDBK cells were infected at 0.5 m.o.i.
of BHV-1. Mock infection was used as a control. The cells
were incubated at 37°C. The cells were washed once
with NET buffer at the end of 12 h p.i. and lysed as
described. Immunoprecipitation was performed using
immobilized protein G cross-linked to 6% agarose beads
(Pierce Chemical, Rockford, IL) as previously described
(Van Drunen Littel-Van Den Hurk et al., 1995). The immu-
noprecipitated proteins were resolved by 10% SDS–
PAGE and transferred to PVDF membrane. The proteins
were visualized by Coomassie blue staining or by a
chemiluminescent detection system using the PY20 an-
tibody as described earlier.
Dose optimization assays for the tyrosine kinase
inhibitors
The trypan blue exclusion test (Lappalainen et al.,
1994) and LDH assay were performed to measure the
cytotoxicity of genistein (Calbiochem) and tyrphostin
(Calbiochem) on MDBK cells. Genistein (5, 25, 50, and
100 mM) and tyrphostin (5, 12.5, 20, and 25 mM) were
tested. DMSO control, the solvent for both genistein and
tyrphostin, was tested at 0.025% for its cytotoxic effect on
the MDBKs. The LDH assay was performed using Cyto-
Tox 96 (Promega, Madison, WI) according to the manu-
facturer’s instruction.Determination of the effect of tyrosine kinase
inhibitors on the viral replication
The effect of the inhibitors on the viral replication was
assessed in actively growing MDBK cells that were sup-
plemented with MEM containing 2% equine serum. The
cells were infected at 0.5 m.o.i. with BHV-1 or BHV-
1gED3.1 and treated with a predetermined optimal dos-
age of respective inhibitors at 37°C in a humidified
atmosphere of 5% CO2. After 24 h p.i., the cells were
scrapped and frozen with the viral supernatant at 270°C.
Before viral titration, the cell lysate was centrifuged at
1000 3 g for 7 min to clarify, and the supernatant was
used. The virus yield was titrated on MDBK cells, and the
TCID50 was calculated using the Reed and Muench for-
ula (Reed and Muench, 1938).
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